(Reuters) – Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
THOUSAND OAKS, Calif., Sept. 20, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) trial evaluating the effect of Repatha® (evolocumab) on… http://www.prnewswire.com/news-releases/amgen-announces-positive-top-line-results-from-phase-3-glagov-imaging-study-of-repatha-evolocumab-300330644.html
THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose… http://www.prnewswire.com/news-releases/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor-300296280.html
(MedPage Today) — Uptake of the new drugs likely to lag a little longer http://www.medpagetoday.com/Cardiology/CardioBrief/58400
[Reuters] – Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain’s healthcare cost watchdog after the manufacturers offered special discounts to the country’s state-run health service. Sanofi’s Praluent, which was developed with Regeneron , and Amgen’s Repatha are both so-called PCSK9 medicines that work in a different way to existing cholesterol fighters such as statins. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that both drugs could be considered for use by people whose cholesterol is still not under control despite trying other treatments. http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/sanofi-amgen-cholesterol-drugs-win-230101015.html
ALEXANDRIA, Va., March 30, 2016 /PRNewswire-USNewswire/ — Patients with high cholesterol should use proven and less expensive therapies, such as statins, before trying the new and more expensive class of specialty cholesterol drugs known as PCSK9 inhibitors, according to recommendations… http://www.prnewswire.com/news-releases/amcp-partnership-forum-on-cholesterol-management-urges-use-of-proven-therapies-and-developing-management-strategies-for-pcsk9-inhibitors-300243546.html